DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Geodon (Ziprasidone Hydrochloride) - Published Studies

 
 



Geodon Related Published Studies

Well-designed clinical trials related to Geodon (Ziprasidone)

A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. [2014]

Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. [2014]

Sleep architecture in ziprasidone-treated bipolar depression: a pilot study. [2013]

Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. [2013]

Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications. [2013]

Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. [2012]

Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. [2012]

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. [2011.10]

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. [2011.04]

Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. [2011.03]

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). [2011.02]

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. [2011]

Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone. [2011]

Ziprasidone for maintenance treatment of bipolar I disorder in adults. [2011]

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. [2011]

Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. [2011]

Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. [2010.12]

Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. [2010.12]

Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. [2010.08.16]

Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. [2010.08]

A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. [2010.08]

Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. [2010.07]

Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. [2010.07]

Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. [2010.04]

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. [2010.04]

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. [2010.03.24]

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. [2010.03]

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. [2010.02]

Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder. [2010.02]

Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. [2010.01]

Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. [2010]

Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. [2010]

Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. [2010]

Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. [2010]

Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. [2010]

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. [2010]

Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol. [2009.11]

Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. [2009.10]

Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. [2009.09]

Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. [2009.08]

Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. [2009.06.19]

Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. [2009.06]

Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. [2009.06]

Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. [2009.05]

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. [2009.05]

The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. [2009.01]

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. [2009]

Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. [2008.10]

A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. [2008.10]

Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. [2008.06]

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. [2008.04]

Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. [2008.04]

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. [2008.04]

Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study. [2008.01.30]

Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. [2007.12]

Ziprasidone, diazepam, or the combination for prevention of cocaine toxicity in a mouse model. [2007.08]

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. [2007.07]

Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. [2007.01]

Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia: A Double-blind, Placebo-Controlled Study. [2007]

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. [2006.05]

Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. [2006.04]

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. [2006.04]

Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. [2006.01]

An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. [2006]

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. [2005.10]

Ziprasidone decreases cortisol excretion in healthy subjects. [2005.09]

Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. [2005.08]

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. [2005.08]

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. [2005.08]

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. [2005.06]

Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. [2005.04]

Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. [2005.01]

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. [2004.12]

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. [2004.10]

The utility of intramuscular ziprasidone in the management of acute psychotic agitation. [2004.07]

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. [2004.05]

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. [2004.03]

The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. [2004.01]

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. [2003.05]

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. [2003.04]

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. [2002.09]

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. [2002.06]

The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. [2002.04]

The apparent effects of ziprasidone on plasma lipids and glucose. [2001.05]

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. [2001.05]

Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies. [2001.02]

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. [2001.01]

Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. [2000.12]

Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. [2000.03]

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. [2000]

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. [2000]

The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. [2000]

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. [1999.05]

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. [1998.11]

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. [1998.08]

The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. [1998.01]

Well-designed clinical trials possibly related to Geodon (Ziprasidone)

Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. [2014]

Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. [2014]

Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. [2014]

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. [2013]

Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. [2013]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017